Literature DB >> 18720524

Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.

L W M Loo1, C Ton, Y-W Wang, D I Grove, H Bouzek, N Vartanian, M-G Lin, X Yuan, T L Lawton, J R Daling, K E Malone, C I Li, L Hsu, P L Porter.   

Abstract

The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we conducted a whole-genome study of 166 archival estrogen receptor (ER)-positive tumors (89 IDC and 77 ILC) using the Affymetrix GeneChip(R) Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high-frequency LOH (>50%) common to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events across the genome than ILC (fractional allelic loss = 0.186 and 0.156). By comparing the average frequency of LOH by chromosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q than ILC tumors. We identified additional chromosomal arms differentiating the subtypes when tumors were stratified by tumor size, mitotic rate, or DNA content. Of 5,754 informative SNPs (>25% informativity), we identified 78 and 466 individual SNPs with a higher frequency of LOH (P < 0.05) in ILC and IDC tumors, respectively. Hierarchical clustering of these 544 SNPs grouped tumors into four major groups based on their patterns of LOH and retention of heterozygosity. LOH in chromosomal arms 8p and 5q was common in higher grade IDC tumors, whereas ILC and low-grade IDC grouped together by virtue of LOH in 16q.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720524      PMCID: PMC2871767          DOI: 10.1002/gcc.20610

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  50 in total

1.  Requirement for XRCC4 and DNA ligase IV in alignment-based gap filling for nonhomologous DNA end joining in vitro.

Authors:  Jae Wan Lee; Steven M Yannone; David J Chen; Lawrence F Povirk
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

2.  Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes.

Authors:  H Buerger; F Otterbach; R Simon; K L Schäfer; C Poremba; R Diallo; C Brinkschmidt; B Dockhorn-Dworniczak; W Boecker
Journal:  J Pathol       Date:  1999-12       Impact factor: 7.996

3.  Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization.

Authors:  K Günther; S Merkelbach-Bruse; B K Amo-Takyi; S Handt; W Schröder; L Tietze
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

4.  Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.

Authors:  P L Porter; A Y El-Bastawissi; M T Mandelson; M G Lin; N Khalid; E A Watney; L Cousens; D White; S Taplin; E White
Journal:  J Natl Cancer Inst       Date:  1999-12-01       Impact factor: 13.506

5.  Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast.

Authors:  Y Ando; H Iwase; S Ichihara; S Toyoshima; T Nakamura; H Yamashita; T Toyama; Y Omoto; S Karamatsu; S Mitsuyama; Y Fujii; S Kobayashi
Journal:  Cancer Lett       Date:  2000-08-11       Impact factor: 8.679

6.  A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.

Authors:  R Roylance; P Gorman; T Papior; Y-L Wan; M Ives; J E Watson; C Collins; N Wortham; C Langford; H Fiegler; N Carter; C Gillett; P Sasieni; S Pinder; A Hanby; I Tomlinson
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

7.  Hormone replacement therapy in relation to breast cancer.

Authors:  Chi-Ling Chen; Noel S Weiss; Polly Newcomb; William Barlow; Emily White
Journal:  JAMA       Date:  2002-02-13       Impact factor: 56.272

Review 8.  WWOX, a chromosomal fragile site gene and its role in cancer.

Authors:  D Ramos; C M Aldaz
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

9.  Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.

Authors:  Christopher I Li; Kathleen E Malone; Peggy L Porter; Thomas J Lawton; Lynda F Voigt; Kara L Cushing-Haugen; Ming Gang Lin; Xiaopu Yuan; Janet R Daling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01       Impact factor: 4.254

10.  Trends in incidence rates of invasive lobular and ductal breast carcinoma.

Authors:  Christopher I Li; Benjamin O Anderson; Janet R Daling; Roger E Moe
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

View more
  10 in total

1.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

Review 2.  Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

Authors:  G S Hwang; R Bhat; R D Crutchley; M V Trivedi
Journal:  Pharmacogenomics J       Date:  2017-08-01       Impact factor: 3.550

3.  Learning oncogenic pathways from binary genomic instability data.

Authors:  Pei Wang; Dennis L Chao; Li Hsu
Journal:  Biometrics       Date:  2011-03       Impact factor: 2.571

4.  Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women.

Authors:  Lenora W M Loo; Yinghui Wang; Erin M Flynn; Mary Jo Lund; Erin J Aiello Bowles; Diana S M Buist; Jonathan M Liff; Elaine W Flagg; Ralph J Coates; J William Eley; Li Hsu; Peggy L Porter
Journal:  Breast Cancer Res Treat       Date:  2011-01-25       Impact factor: 4.872

5.  Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.

Authors:  Min Fang; Jessica Toher; Martin Morgan; Jerry Davison; Susan Tannenbaum; Kevin Claffey
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

6.  Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.

Authors:  Hiltrud Brauch; Matthias Schwab
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

7.  Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.

Authors:  Masahiro Oikawa; Koh-ichiro Yoshiura; Hisayoshi Kondo; Shiro Miura; Takeshi Nagayasu; Masahiro Nakashima
Journal:  Radiat Oncol       Date:  2011-12-07       Impact factor: 3.481

8.  p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.

Authors:  Patrick Lebok; Magdalena Roming; Martina Kluth; Christina Koop; Cansu Özden; Berivan Taskin; Khakan Hussein; Annette Lebeau; Isabell Witzel; Linn Wölber; Stefan Geist; Peter Paluchowski; Christian Wilke; Uwe Heilenkötter; Volkmar Müller; Barbara Schmalfeldt; Ronald Simon; Guido Sauter; Luigi Terracciano; Rainer Horst Krech; Albert von der Assen; Eike Burandt
Journal:  Oncotarget       Date:  2016-12-06

9.  Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma.

Authors:  Logan C Walker; Margaret McDonald; J Elisabeth Wells; Gavin C Harris; Bridget A Robinson; Christine M Morris
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

10.  CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Authors:  M A Province; M P Goetz; H Brauch; D A Flockhart; J M Hebert; R Whaley; V J Suman; W Schroth; S Winter; H Zembutsu; T Mushiroda; W G Newman; M-T M Lee; C B Ambrosone; M W Beckmann; J-Y Choi; A-S Dieudonné; P A Fasching; R Ferraldeschi; L Gong; E Haschke-Becher; A Howell; L B Jordan; U Hamann; K Kiyotani; P Krippl; D Lambrechts; A Latif; U Langsenlehner; W Lorizio; P Neven; A T Nguyen; B-W Park; C A Purdie; P Quinlan; W Renner; M Schmidt; M Schwab; J-G Shin; J C Stingl; P Wegman; S Wingren; A H B Wu; E Ziv; G Zirpoli; A M Thompson; V C Jordan; Y Nakamura; R B Altman; M M Ames; R M Weinshilboum; M Eichelbaum; J N Ingle; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.